Creation of an Annotated Library on FDA Approved Nanomedicines by Hodson, Marley R et al.
Virginia Commonwealth University
VCU Scholars Compass
Undergraduate Research Posters Undergraduate Research Opportunities Program
2015
Creation of an Annotated Library on FDA
Approved Nanomedicines
Marley R. Hodson
Virginia Commonwealth University, hodsonmr@mymail.vcu.edu
Tanin Izadi
Virginia Commonwealth University, izadit2@mymail.vcu.edu
Nastassja Lewinski Ph.D
Virginia Commonwealth University, nalewinski@vcu.edu
Bridget T. McInnes Ph.D
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/uresposters
Part of the Biochemical and Biomolecular Engineering Commons, Nanomedicine Commons,
and the Other Chemical Engineering Commons
© The Author(s)
This Book is brought to you for free and open access by the Undergraduate Research Opportunities Program at VCU Scholars Compass. It has been
accepted for inclusion in Undergraduate Research Posters by an authorized administrator of VCU Scholars Compass. For more information, please
contact libcompass@vcu.edu.
Downloaded from
Hodson, Marley R.; Izadi, Tanin; Lewinski, Nastassja Ph.D; and McInnes, Bridget T. Ph.D, "Creation of an Annotated Library on FDA
Approved Nanomedicines" (2015). Undergraduate Research Posters. Poster 170.
http://scholarscompass.vcu.edu/uresposters/170
Creation of an Annotated Library on FDA Approved Nanomedicines 
Tanin Izadi1, Marley Hodson1, Bridget T. McInnes, Ph.D.2, Nastassja Lewinski, Ph.D.1 
1Department of Chemical & Life Science Engineering  2Department of Computer Science 
 
Abstract 
Nanomedicine is a type of nanotechnology used in the medical field to 
limit the dosage amount and target drug delivery to specific cells. 
Nanomedicines that are approved and used tend to be extremely 
successful; however despite over a decade of research, only a limited 
number of nanomedicines have advanced for clinical use. A possible 
reason for the numerous nanomedicine failures is lack of easily 
accessible information and research on previous nanomedicines. In this 
project, we have compiled nanomedicine labeling information from the 
Drugs@FDA website. We have extracted phrases/sentences from labels 
relating to keywords on nanomaterial properties and drug profile 
characteristics. In the future, we plan to incorporate discontinued 
nanomedicines, nanomedicines on the market, and nanomedicines in 
different clinical trial phases. By compiling the descriptions and 
contents of a set of specific nanomedicines, a machine learning program 
could be developed to comb through literature and automatically 
identify similar nanomedicine related entities. Our research works to 
provide an easier and quicker method to obtain specific information on 
approved nanomedicines. 
Introduction 
We are used to information being readily accessible. When it comes to 
the subject of nanomedicine that is no longer the case. The innovative 
world of nanomedicine hasn’t evolved to its full advancing potential. 
The application of nanotechnology for medical purposes has the 
potential to greatly improve our world. 
Results/Discussion 
 After our thorough research and analysis of each nanomedicine, we 
were able to group and categorize the drugs based on their platforms 
and indications. When categorizing these characteristics we found 
different trends and correlations. There were seven total nanomedicines 
that had the indication of antineoplastic agents (medicines that target 
cancerous cells). Out of the seven antineoplastic nanomedicines, six had 
the platform of either a liposome or micelle. While liposomes and 
micelles share many similar qualities, the structure remains as the 
predominant difference. Micelles have a membrane monolayer, while 
liposomes have a bilayer, signifying the liposomes are generally larger 
in size. We conclude from this trend that encapsulating the drug in a 
liposomes and micelles is a more successful drug delivery method 
compared to attaching the drug to the surface of the particles. With 
many new nanomedicines in the pipeline, this trend can easily change in 
the future. 
Conclusion 
As we continue our research, we plan to work with Dr. McInnes’s 
research team to develop a system that automatically extracts 
nanomedicine information. With the sentences we have collected and 
categorized, the system will be able to search for entities within the label 
information pdfs. With this entity extraction program, we will be able to 
promptly gather the relevant nanomedicine information. The shortened 
period for research allows for a clearer and quicker alternative in 
viewing the relationships between the different types of nanomedicines. 
Once the automation program is created, the current difficulties in 
retrieving background research on nanomaterials will dramatically 
decrease. This program will be able to extract entities from pdf files that 
the user inputs. A separate program that automatically searches for 
nanomedicine pdfs is also under development. 
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Methods 
Our initial database was based off of the work by Schutz et al. [3].  Figure 3  
shows our Excel spreadsheet and consists of data collected from this paper. The 
Drugs@FDA website has been our primary source for retrieving nanomedicine 
labeling information.  We extracted relevant data from the label information, 
which consisted of entities in the form of a phrase/sentence relating to 
nanomaterial properties and drug profile characteristics. These entities 
specifically included the trade name, phase, platform, surface coating, 
nanoparticle, max concentration, time to max concentration, generic/other name, 
company, indication, clearance, volume of distribution, active ingredient, size, 
route of administration, dose, dose form, plasma half life, and elimination half 
life. After the data was extracted, the sentences containing this data were placed 
into a separate Excel spreadsheet as shown in Figure 4. Figure 3 contains the 
entire database that was updated and filled with information received from the 
labeling documents during this project.  The data was then analyzed to reveal 
any potential trends. 
Figure 1. Different types of nanoparticles and ways they 
can be modified and developed [Image source: Ref. 1] 
 
Figure 2. Illustration of a magnetic 
nanoparticle’s “core-shell” structure. 
This example has a iron oxide core, 
which is common among magnetic 
nanoparticles. [Image source: Ref. 2] 
 
Figure 5. 
Prevalence of 
the different 
uses of FDA 
approved 
nanomedicines. 
Antineoplastics 
was the most 
common. 
Figure 6. Prevalence 
of the different 
platforms each 
nanomedicine 
contained. 
Liposomes were the 
top platform used 
followed by 
Nanoparticles 
Figure 4. 
Screenshot 
of our 
sentence 
extraction 
excel 
spreadsheet 
for the 
drug 
Zevalin.  
Figure 3. Screenshot of entire updated database. 
